Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting AML-associated FLT3 mutations with a type I kinase inhibitor.
Jones LM, Melgar K, Bolanos L, Hueneman K, Walker MM, Jiang JK, Wilson KM, Zhang X, Shen J, Jiang F, Sutter P, Wang A, Xu X, Tawa GJ, Hoyt SB, Wunderlich M, O'Brien E, Perentesis JP, Starczynowski DT, Thomas CJ. Jones LM, et al. Among authors: wunderlich m. J Clin Invest. 2020 Apr 1;130(4):2017-2023. doi: 10.1172/JCI127907. J Clin Invest. 2020. PMID: 32149729 Free PMC article.
Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.
Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, Goyama S, Jansen G, Cloos J, Rigolino C, Cortelezzi A, Mulloy JC, Oliva EN, Cuzzola M, Starczynowski DT. Fang J, et al. Among authors: wunderlich m. Blood. 2012 Jul 26;120(4):858-67. doi: 10.1182/blood-2012-02-407999. Epub 2012 Jun 8. Blood. 2012. PMID: 22685174 Free PMC article.
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.
Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, Mathews L, Ferrer M, Southall N, Guha R, Keller J, Thomas C, Beverly LJ, Cortelezzi A, Oliva EN, Cuzzola M, Maciejewski JP, Mulloy JC, Starczynowski DT. Rhyasen GW, et al. Among authors: wunderlich m. Cancer Cell. 2013 Jul 8;24(1):90-104. doi: 10.1016/j.ccr.2013.05.006. Cancer Cell. 2013. PMID: 23845443 Free PMC article.
Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells.
Goyama S, Schibler J, Cunningham L, Zhang Y, Rao Y, Nishimoto N, Nakagawa M, Olsson A, Wunderlich M, Link KA, Mizukawa B, Grimes HL, Kurokawa M, Liu PP, Huang G, Mulloy JC. Goyama S, et al. Among authors: wunderlich m. J Clin Invest. 2013 Sep;123(9):3876-88. doi: 10.1172/JCI68557. Epub 2013 Aug 27. J Clin Invest. 2013. PMID: 23979164 Free PMC article.
An MDS xenograft model utilizing a patient-derived cell line.
Rhyasen GW, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy JC, Starczynowski DT. Rhyasen GW, et al. Among authors: wunderlich m. Leukemia. 2014 May;28(5):1142-5. doi: 10.1038/leu.2013.372. Epub 2013 Dec 11. Leukemia. 2014. PMID: 24326684 Free PMC article. No abstract available.
Overcoming adaptive therapy resistance in AML by targeting immune response pathways.
Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, Jiang JK, Wilson KM, Zhang X, Sutter P, Wang A, Xu X, Choi K, Tawa G, Lorimer D, Abendroth J, O'Brien E, Hoyt SB, Berman E, Famulare CA, Mulloy JC, Levine RL, Perentesis JP, Thomas CJ, Starczynowski DT. Melgar K, et al. Among authors: wunderlich m. Sci Transl Med. 2019 Sep 4;11(508):eaaw8828. doi: 10.1126/scitranslmed.aaw8828. Sci Transl Med. 2019. PMID: 31484791 Free PMC article.
Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia.
Hayashi Y, Goyama S, Liu X, Tamura M, Asada S, Tanaka Y, Fukuyama T, Wunderlich M, O'Brien E, Mizukawa B, Yamazaki S, Matsumoto A, Yamasaki S, Shibata T, Matsuda K, Sashida G, Takizawa H, Kitamura T. Hayashi Y, et al. Among authors: wunderlich m. Nat Commun. 2019 Oct 25;10(1):4869. doi: 10.1038/s41467-019-12555-1. Nat Commun. 2019. PMID: 31653912 Free PMC article.
314 results